Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 3, 2012, Pages 341-352

  Climent, Miguel A ^a   Piulats, Josep M ^b   Sánchez Hernández, Alfredo ^c   Arranz, José Ángel ^d   Cassinello, Javier ^e   García Donas, Jesús ^f   González del Alba, Aránzazu ^g   León Mateos, Luis ^h   Mellado, Begoña ⁱ   Méndez Vidal, M José ^j   Pérez Valderrama, Begoña ^k  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b Institut Català d'Oncologia ICO   (Spain)

^c Hospital Provincial de Castellon   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^f HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^g HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^h Instituto de Salud Carlos III   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

more..

Author keywords

Antineoplasic protocols; Castration resistant prostate cancer; Guidelines; Neoplasm; Treatment outcome

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; CABAZITAXEL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; HYDROCORTISONE; KETOCONAZOLE; LEXIDRONAM SAMARIUM SM 153; MITOXANTRONE; NAVELBINE; PHOSPHORUS 32; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SAMARIUM 153; SIPULEUCEL T; STRONTIUM 89; TESTOSTERONE; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RECHALLENGE; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FLUID RETENTION; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; JAW OSTEONECROSIS; LEUKOCYTE COUNT; LOW DRUG DOSE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; METATATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORCHIECTOMY; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SPINAL CORD COMPRESSION; TESTOSTERONE BLOOD LEVEL; THROMBOCYTE COUNT; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; TAXOIDS;

EID: 84864722629     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.01.002     Document Type: Review

References (47)

1. Sackett D.L. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1986, 89:2S-3S.
2. Droz J.P., Balducci L., Bolla M., et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010, 73:68-91.
3. Droz J.P., Balducci L., Bolla M., et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010, 106:462-469.
4. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
5. Chao D., Harland S.J. The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer. Eur Urol 1997, 31:7-10.
6. Taylor C.D., Elson P., Trump D.L. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993, 11:2167-2172.
7. Hussain M., Wolf M., Marshall E., Crawford E.D., Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994, 12:1868-1875.
8. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17:3461-3467.
9. Sartor A.O., Tangen C.M., Hussain M.H., et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008, 112:2393-2400.
10. Small E.J., Halabi S., Dawson N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004, 22:1025-1033.
11. Harris K.A., Weinberg V., Bok R.A., Kakefuda M., Small E.J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002, 168:542-545.
12. Procopio G., Guadalupi V., Giganti M.O., et al. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU Int 2010.
13. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506-2513.
14. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
15. Small E.J., Schellhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089-3094.
16. Higano C.S., Schellhammer P.F., Small E.J., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
17. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010, 363:411-422.
18. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:1966-1998.
19. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 2004, 351:1513-1520.
20. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004, 351:1502-1512.
21. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
22. Berthold D.R., Pond G.R., Roessner M., de Wit R., Eisenberger M., Tannock A.I. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008, 14:2763-2767.
23. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., de Wit R., Tannock I.F., Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007, 13:6396-6403.
24. O'Donnell A., Judson I., Dowsett M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004, 90:2317-2325.
25. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008, 26:4563-4571.
26. Reid A.H., Attard G., Danila D.C., et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010, 28:1489-1495.
27. Danila D.C., Morris M.J., de Bono J.S., et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010, 28:1496-1501.
28. de Bono J.S., Logothetis C.J., FIzazi K., et al. ESMO 2010 late-breaking abstracts - abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (PTS) with metastasis castration-resistant prostate cancer (MCRPC) who have progressed after docetaxel-based chemotherapy (CHEMO): results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Ann Oncol 2010, 21:viii3. Abstract LBA5.
29. Bissery M.-C., Vrignaud P., Combeau C., et al. Preclinical evaluation of XRP9881A, a new taxoid. AACR meeting abstracts 2004, 1253.
30. Mita A.C., Denis L.J., Rowinsky E.K., et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009, 15:723-730.
31. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
32. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
33. Buonerba C., Palmieri G., Di Lorenzo G. Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. Eur Urol 2010, 58:636-637.
34. Eymard J.C., Oudard S., Gravis G., et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010, 106:974-978.
35. Loriot Y., Massard C., Gross-Goupil M., et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010, 46:1770-1772.
36. Di Lorenzo G, Autorino R, Aieta M, et al. 2010 Genitourinary cancers symposium - phase II study of docetaxel retreatment in docetaxel-pretreated castration-resistant prostate cancer. Abstract No. 47. Available at: [accessed 30.05.11]. http://www.asco.org/ascov2/Meetings/Abstracts%3F%26vmview=abst_detail_view%26confID=73%26abstractID=30106.
37. Abratt R.P., Brune D., Dimopoulos M.A., et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 2004, 15:1613-1621.
38. Nelius T., Klatte T., de Riese W., Haynes A., Filleur S. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol 2010, 27:363-367.
39. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
40. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
41. Coleman R.E. Risks and benefits of bisphosphonates. Br J Cancer 2008, 98:1736-1740.
42. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
43. Oosterhof G.O., Roberts J.T., de Reijke T.M., et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003, 44:519-526.
44. Sartor O., Reid R.H., Hoskin P.J., et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004, 63:940-945.
45. Serafini A.N., Houston S.J., Resche I., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998, 16:1574-1581.
46. Sartor O., Reid R.H., Bushnell D.L., Quick D.P., Ell P.J. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007, 109:637-643.
47. Overall survival benefit of radium-223 chloride (Alpharadin(TM)) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Press Release: Algeta ASA - Tuesday September 13, 2011. Available at: [accessed 23.11.11]. http://finance.yahoo.com/news/Alpharadin-Phase-III-Trial-thomsonreuters-3781430460.html.